Discover ioCells

Programmed identity
in every cell

iocells_vial_radial_0

Mature, functional human
iPSC-derived cells within days,
powered by opti-ox™

The future of human health will be defined by technologies that accelerate the world's access to more effective medicines.

Human cells are a cornerstone of fundamental disease research, drug discovery, and clinical translation. Yet, despite decades of research into iPSCs, emerging cures for some of the world’s most pervasive diseases have been bottlenecked by a lack of access to standardised, easy to use and readily accessible human cells.

We built ioCells to solve this challenge.

Developed on our platform, and powered by opti-ox technology, ioCells are human cells precision reprogrammed from iPSCs consistently, at scale. With ioCells, scientists no longer need to battle with variance, unreliability, physiological irrelevance and long experimental timelines. Instead, scientists can finally focus on the next great advances in human health.

ioCells are for research use only.

Browse ioCells portfolio

ioSkeletal-Myocytes-2550px_wide

ioWild Type Cells™

ioWild Type Cells are defined, easy-to-use, functional iPSC-derived human cells from a healthy donor background that are ready for fundamental research and drug discovery experimentation within days.

a.HTT50CAGWT_Overlay__TUBB3(G)_MAP2(R)_DAPI(B)_

ioDisease Model Cells™

ioDisease Model Cells are ioWild Type Cells engineered to contain disease-relevant mutations. ioDisease Model Cells and ioWild Type Cells form an isogenic pair allowing scientists to make true comparisons.

Benchtop benefits

consistent_0

Consistent

Our platform ensures consistency between every batch of cells, overcoming the challenge of data reproducibility.

cost_0

Cost-effective

ioCells generate quality data at industry leading seeding densities. You can do more with every vial as every well saves you money.

defined_0

Defined

Every ioCell has its identity characterised by ICC, RT-qPCR and RNA-Seq at minimum.

easy_0

Easy-to-use

ioCells are delivered cryopreserved and require a simple protocol using an open-source medium to get started.

quick_0

Quick

Precision reprogrammed cells mature rapidly, meaning cells are ready for experimentation and data gathering within days post-revival.

scalable_0

Scalable

With opti-ox technology we can make billions of consistently reprogrammed cells, surpassing the demands of industrial workflows.

Our precision reprogramming technology

 

opti-ox-cell_7fps_v03_00033

Every ioCell is powered by opti-ox.

With opti-ox, we take inducible genetic programs that are coded to define cell fate, and integrate them into regions of the genome that are not affected by gene silencing. This precise control drives a programmed identity in every cell, and means human iPSCs can be reprogrammed into any cell type.

Each vial of ioCells contains a defined and known cell identity and purity. Consistency between batches eliminates the need to re-validate for every experiment. As a result, ioCells are ready for quality data production in a matter of days. 

Custom cell development

Partner with us. Access our cell identity coding platform to generate custom ioCells precision reprogrammed to precisely answer your drug discovery, cell therapy or disease research questions.

bit.bio_Lab_custom cell development

Product resources

Development and characterisation of a robust in vitro disease model to study tauopathies Poster
Development and characterisation of a robust in vitro disease model to study tauopathies
V1
2022
Charles River & bit.bio
Download
Validation of ALS-relevant phenotypes in precision reprogrammed iPSC-derived glutamatergic Neurons containing a TDP-43 M337V mutation. Poster
Validation of ALS-relevant phenotypes in precision reprogrammed iPSC-derived glutamatergic Neurons containing a TDP-43 M337V mutation.
V1
2022
Charles River & bit.bio
Download
Interferon-γ exposure of human iPSC-derived neurons alters major histocompatibility complex I and synapsin protein expression | Publication Publication
Interferon-γ exposure of human iPSC-derived neurons alters major histocompatibility complex I and synapsin protein expression | Publication

Pavinlek., et al | Frontiers in Psychiatry

2022

 

Using ioGlutamatergic Neurons

 

 

Read more
Glutamatergic Neurons and Brain Cyst Formation | Publication Publication
Glutamatergic Neurons and Brain Cyst Formation | Publication

Bando., et al | Frontiers in Cellular and Infection Microbiology

2022

 

Using ioGlutamatergic Neurons

 

 

Read more
Compounds co-targeting kinases in axon regulatory pathways promote regeneration and behavioral recovery after spinal cord injury in mice | Publication Publication
Compounds co-targeting kinases in axon regulatory pathways promote regeneration and behavioral recovery after spinal cord injury in mice | Publication

Mah., et al | Experimental Neurology

2022

 

Using ioGlutamatergic Neurons

Read more
Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human stem cell models Webinar
Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human stem cell models

Dr Deepak Srivastava | King’s College London

Watch now
Partnering with Charles River to advance CNS drug discovery with ioGlutamatergic Neurons™ Video
Partnering with Charles River to advance CNS drug discovery with ioGlutamatergic Neurons™

Charles River

Watch now
In Conversation with Charles River Video
In Conversation with Charles River

Dr Marijn Vlaming | Head of Biology
Charles River

Watch now
Stem Cells and Functional Genomic Screening | Talk Talk
Stem Cells and Functional Genomic Screening | Talk

Kam Dhaliwal | SVP Strategic Alliances


Talk at ELRIG CRISPR in Drug Discovery

Watch now
High Content Analysis of 2D and 3D cellular models for target and phenotypic drug discovery Poster
High Content Analysis of 2D and 3D cellular models for target and phenotypic drug discovery

Lachize | et al
Courtesy of Charles River Laboratories

Download
Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery Talk
Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Kam Dhaliwal SVP Strategic Alliances
Dr Thomas Moreau | Head of Research


Talk at ELRIG Drug Discovery Digital

Watch now
Molecular and functional characterization of stem cells-derived glutamatergic neurons in support of drug discovery applications Poster
Molecular and functional characterization of stem cells-derived glutamatergic neurons in support of drug discovery applications

Iovino | et al
Courtesy of Charles River

Download

Related pages

Resources Explore our latest scientific insights, webinars, blogs and videos
Our platform Discover the cell identity coding platform that powers our ioCells
News Read our latest updates and press coverage